$EOLS
Evolus, Inc. Stock $eols

$eols Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000157056221000173 Filed on November 02, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$34.66M	$26.68M	$17.66M
YoY Change	68.4%	51.05%	34.13%
Cost Of Revenue	$15.83M	$11.49M	$4.854M
YoY Change	117.5%	136.71%	30.55%
Gross Profit	$18.82M	$15.19M	$12.81M
YoY Change	41.53%	18.58%	35.54%
Gross Profit Margin	54.31%	56.93%	72.52%
Selling, General & Admin	$33.23M	$31.69M	$21.94M
YoY Change	21.34%	44.39%	-28.98%
% of Gross Profit	176.56%	208.63%	171.34%
Research & Development	$423.0K	$301.0K	$350.0K
YoY Change	-41.25%	-14.0%	-49.49%
% of Gross Profit	2.25%	1.98%	2.73%
Depreciation & Amortization	$920.0K	$923.0K	$1.744M
YoY Change	-51.06%	-47.08%	45.09%
% of Gross Profit	4.89%	6.08%	13.62%
Operating Expenses	$34.58M	$31.99M	$21.57M
YoY Change	15.33%	48.31%	-37.64%
Operating Profit	-$15.75M	-$19.12M	-$8.760M
YoY Change	-5.55%	118.29%	-65.15%
Interest Expense	-$140.0K	-$311.0K	-$2.730M
YoY Change	-95.04%	-88.61%	36.5%
% of Operating Profit
Other Income/Expense, Net		-$311.0K	-$2.758M
YoY Change		-88.72%	12.34%
Pretax Income	-$18.14M	-$19.43M	-$11.49M
YoY Change	-83.64%	69.19%	-57.67%
Income Tax	$42.00K	$0.00	-$27.00K
% Of Pretax Income
Net Earnings	-$18.18M	-$19.43M	-$11.46M
YoY Change	-83.58%	69.59%	-57.53%
Net Earnings / Revenue	-52.45%	-72.85%	-64.88%
Basic Earnings Per Share		-$0.35	-$0.34
Diluted Earnings Per Share	-$326.7K	-$0.35	-$0.34
COMMON SHARES
Basic Shares Outstanding	55.58M shares	55.01M shares	33.75M shares
Diluted Shares Outstanding		55.01M shares	33.75M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$146.3M	$107.8M	$110.1M
YoY Change	35.97%	-2.11%	48.76%
Cash & Equivalents	$146.3M	$107.8M	$85.13M
Short-Term Investments	$0.00	$0.00	$25.00M
Other Short-Term Assets	$11.04M	$8.959M	$6.000M
YoY Change	404.66%	49.32%	53.85%
Inventory	$1.762M	$3.816M	$4.871M
Prepaid Expenses	$5.082M	$4.484M
Receivables	$14.66M	$13.29M	$11.40M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$178.8M	$138.3M	$132.4M
YoY Change	40.11%	4.49%	39.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.371M	$1.058M	$1.362M
YoY Change	5.71%	-22.32%	38.41%
Goodwill	$21.21M	$21.21M	$21.21M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$50.63M	$51.47M	$56.79M
YoY Change	-8.45%	-9.37%	-5.12%
Long-Term Investments
YoY Change
Other Assets	$2.758M	$240.0K	$440.0K
YoY Change	1049.17%	-45.45%	-63.18%
Total Long-Term Assets	$78.68M	$76.88M	$83.38M
YoY Change	-3.4%	-7.8%	-4.69%
TOTAL ASSETS
Total Short-Term Assets	$178.8M	$138.3M	$132.4M
Total Long-Term Assets	$78.68M	$76.88M	$83.38M
Total Assets	$257.5M	$215.2M	$215.8M
YoY Change	23.16%	-0.26%	18.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.091M	$7.365M	$2.957M
YoY Change	-36.65%	149.07%	-51.72%
Accrued Expenses	$29.99M	$23.44M	$6.425M
YoY Change	229.52%	264.76%	-55.31%
Deferred Revenue	$7.934M	$5.751M	$2.371M
YoY Change	157.51%	142.56%
Short-Term Debt	$0.00	$19.95M	$0.00
YoY Change	-100.0%
Long-Term Debt Due	$0.00	$0.00
YoY Change	-100.0%
Total Short-Term Liabilities	$57.66M	$71.30M	$12.71M
YoY Change	-68.01%	461.04%	-51.07%
LONG-TERM LIABILITIES
Long-Term Debt	$71.22M	$0.00	$133.0M
YoY Change	75.86%	-100.0%	81.74%
Other Long-Term Liabilities	$46.68M	$46.49M	$34.80M
YoY Change	-23.72%	33.59%	-28.4%
Total Long-Term Liabilities	$117.9M	$46.49M	$167.8M
YoY Change	15.93%	-72.3%	129.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$57.66M	$71.30M	$12.71M
Total Long-Term Liabilities	$117.9M	$46.49M	$167.8M
Total Liabilities	$175.6M	$117.8M	$180.7M
YoY Change	-37.73%	-34.79%	9.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$422.9M	-$404.7M	-$265.4M
YoY Change	12.45%	52.5%	33.66%
Common Stock	$1.000K	$1.000K	$1.000K
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$81.88M	$97.40M	$35.10M
YoY Change
Total Liabilities & Shareholders Equity	$257.5M	$215.2M	$215.8M
YoY Change	23.16%	-0.26%	18.13%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$18.18M	-$19.43M	-$11.46M
YoY Change	-83.58%	69.59%	-57.53%
Depreciation, Depletion And Amortization	$920.0K	$923.0K	$1.744M
YoY Change	-51.06%	-47.08%	45.09%
Cash From Operating Activities	-$9.044M	-$32.13M	-$13.72M
YoY Change	300.18%	134.15%	-45.34%
INVESTING ACTIVITIES
Capital Expenditures	-$390.0K	$21.00K	-$700.0K
YoY Change	30.0%	-103.0%	9.37%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$30.00M
YoY Change	-100.0%	-100.0%	-14.36%
Cash From Investing Activities	-$390.0K	$21.00K	$29.30M
YoY Change	-101.98%	-99.93%	-14.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	47.89M	8.163M	39.77M
YoY Change		-79.47%	-8745.65%
NET CHANGE
Cash From Operating Activities	-9.044M	-32.13M	-13.72M
Cash From Investing Activities	-390.0K	21.00K	29.30M
Cash From Financing Activities	47.89M	8.163M	39.77M
Net Change In Cash	38.46M	-23.94M	55.35M
YoY Change	120.53%	-143.25%	526.84%
FREE CASH FLOW
Cash From Operating Activities	-$9.044M	-$32.13M	-$13.72M
Capital Expenditures	-$390.0K	$21.00K	-$700.0K
Free Cash Flow	-$8.654M	-$32.15M	-$13.02M
YoY Change	341.53%	146.9%	-46.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001570562
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q3	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020Q3	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38381
	dei	Entity Registrant Name EntityRegistrantName	EVOLUS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1385614
	dei	Entity Address Address Line1 EntityAddressAddressLine1	520 Newport Center Drive Suite 1200
	dei	Entity Address City Or Town EntityAddressCityOrTown	Newport Beach
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92660
	dei	City Area Code CityAreaCode	(949)
	dei	Local Phone Number LocalPhoneNumber	284-4555
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.00001 per share
	dei	Trading Symbol TradingSymbol	EOLS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55576988	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	107796000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102562000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	5000000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13289000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9680000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	3816000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	3354000	USD
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4484000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4828000	USD
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	8959000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2188000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	138344000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	127612000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1058000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1297000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2902000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3414000	USD
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	51468000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	55297000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	21208000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	240000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	240000	USD
CY2021Q3	us-gaap	Assets Assets	215220000	USD
CY2020Q4	us-gaap	Assets Assets	209068000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	7365000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9615000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23436000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9102000	USD
CY2021Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	USD
CY2020Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	63421000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1252000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1212000	USD
CY2021Q3	eols	Contingent Royalty Obligation Payableto Related Party Current ContingentRoyaltyObligationPayabletoRelatedPartyCurrent	4300000	USD
CY2020Q4	eols	Contingent Royalty Obligation Payableto Related Party Current ContingentRoyaltyObligationPayabletoRelatedPartyCurrent	3446000	USD
CY2021Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	19950000	USD
CY2020Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	19068000	USD
CY2021Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	0	USD
CY2020Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	74384000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	71303000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	180248000	USD
CY2021Q3	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	5000000	USD
CY2020Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	20000000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2488000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3147000	USD
CY2021Q3	us-gaap	Contractual Obligation ContractualObligation	39000000	USD
CY2020Q4	us-gaap	Contractual Obligation ContractualObligation	38100000	USD
CY2021Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	40506000	USD
CY2021Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	25000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	25000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	117816000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	282026000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55553792	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55553792	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33749228	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33749228	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	502108000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	303113000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-404705000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-376072000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	97404000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-72958000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	215220000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	209068000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26677000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17661000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	65016000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	35963000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11490000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4854000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	27700000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11021000	USD
CY2021Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2020Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	25500000	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31685000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21944000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	78834000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	70796000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	301000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	350000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1641000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1003000	USD
CY2021Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1400000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-4049000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	9922000	USD
CY2020Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	2471000	USD
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	923000	USD
CY2020Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1744000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4702000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5151000	USD
CY2021Q3	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2020Q3	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	2956000	USD
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	45799000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	26421000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	91426000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	81005000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19122000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8760000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26410000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-45042000	USD
CY2021Q3	us-gaap	Investment Income Net InvestmentIncomeNet	0	USD
CY2020Q3	us-gaap	Investment Income Net InvestmentIncomeNet	32000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	1000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	630000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-311000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2758000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1256000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7680000	USD
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-968000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19433000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11486000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28633000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-52092000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-27000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	227000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-19433000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-11459000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-28633000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-52319000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-16000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19433000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11475000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28633000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52322000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.55
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.55
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55007132	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55007132	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33748690	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33748690	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47818288	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47818288	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33734014	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33734014	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	79457000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2665000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19735000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	219000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	62606000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2328000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-21125000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-206000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	43603000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2967000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-11459000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-16000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	35095000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-72958000	USD
CY2021Q1	eols	Stock Issued During Period Values Litigation Settlement StockIssuedDuringPeriodValuesLitigationSettlement	48421000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	39808000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1606000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	6401000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	23289000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	644000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2887000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-15601000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	106138000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2496000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-19433000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	97404000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-28633000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-52319000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4702000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5151000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6927000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7954000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	501000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2439000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	420000	USD
	eols	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	512000	USD
	eols	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	490000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	882000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1993000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	272000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	203000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	179000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	4049000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-9922000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-968000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4110000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3177000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7161000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1536000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-344000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	681000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1296000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2312000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2845000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	14334000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6926000	USD
	eols	Increase Decrease In Accrued Litigation Settlement IncreaseDecreaseInAccruedLitigationSettlement	-15000000	USD
	eols	Increase Decrease In Accrued Litigation Settlement IncreaseDecreaseInAccruedLitigationSettlement	0	USD
	eols	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-619000	USD
	eols	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-556000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24344000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55605000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	798000	USD
	us-gaap	Payments For Software PaymentsForSoftware	580000	USD
	us-gaap	Payments For Software PaymentsForSoftware	2041000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	74668000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	5000000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	70000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4420000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7507000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	76323000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	522000	USD
	eols	Payments Of Contingent Royalty Obligation PaymentsOfContingentRoyaltyObligation	2295000	USD
	eols	Payments Of Contingent Royalty Obligation PaymentsOfContingentRoyaltyObligation	1131000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	40000000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	214000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25158000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	38347000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5234000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-24765000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102562000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109892000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107796000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85127000	USD
	us-gaap	Interest Paid Net InterestPaidNet	79000	USD
	us-gaap	Interest Paid Net InterestPaidNet	5443000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	39808000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	eols	Stock Issued For Accrued Litigation Settlement Expense StockIssuedForAccruedLitigationSettlementExpense	48421000	USD
	eols	Stock Issued For Accrued Litigation Settlement Expense StockIssuedForAccruedLitigationSettlementExpense	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	81000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-19433000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-28633000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24344000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	107796000	USD
CY2021Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	19950000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-404705000	USD
CY2021Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	25500000	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain comparative amounts for prior year have been reclassified to conform to current year presentations. Such reclassifications did not affect net income or retained earnings.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make certain estimates and assumptions in order to prepare financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company’s most significant estimates relate to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations, stock-based compensation and royalty obligations, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company’s actual results could differ materially from those estimates.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the full impact of the COVID-19 outbreak is unknown and cannot be reasonably estimated. However, where possible, management has made appropriate accounting estimates with respect to certain accounting matters, which include the fair value of royalty obligations, allowance for doubtful accounts, inventory valuation and impairment assessments of goodwill and other long-lived assets, based on the facts and circumstances available as of the reporting date. The Company’s future assessment of the magnitude and duration of the COVID-19 outbreak, as well as other factors, could result in material impacts to the Company’s financial statements in future reporting periods.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, Evolus and Daewoong Pharmaceutical Co. Ltd. (“Daewoong”) entered into an agreement (the “Daewoong Agreement”), pursuant to which the Company received an exclusive distribution license to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, Russia, certain members of the Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company’s commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States in May 2019 and in Canada through its distribution partner in October 2019 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company’s business and its financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company’s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the need for additional financing to achieve its goals, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by physicians and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak and restrictions intended to slow the spread of COVID-19, including quarantines, government-mandated actions, stay-at-home orders and other restrictions, have adversely affected the Company’s business in a number of ways, which have resulted, and may continue to result, in a period of business disruption and in reduced sales and operations. In addition, any disruption and volatility in the global capital markets may increase the Company’s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company’s business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company’s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company’s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of </span></div>various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers’ ability to pay.
	eols	Rebates And Coupons Credits And Payments RebatesAndCouponsCreditsAndPayments	12607000	USD
CY2021Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	25500000	USD
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2020Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2021Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5751000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3081000	USD
CY2021Q3	eols	Rebates And Coupons Credits And Payments RebatesAndCouponsCreditsAndPayments	3912000	USD
	eols	Rebates And Coupons Credits And Payments RebatesAndCouponsCreditsAndPayments	9355000	USD
CY2021Q3	eols	Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability	2695000	USD
	eols	Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability	6686000	USD
CY2020Q3	eols	Rebates And Coupons Credits And Payments RebatesAndCouponsCreditsAndPayments	2378000	USD
CY2020Q3	eols	Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability	806000	USD
	eols	Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability	11945000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2802000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2381000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2118000	USD
CY2021Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	188000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	501000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	23000	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	214000	USD
CY2020Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-168000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2439000	USD
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	171000	USD
CY2020Q4	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	83421000	USD
CY2021Q1	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	48421000	USD
CY2021Q3	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	5000000	USD
CY2021Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	USD
CY2020Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	63421000	USD
CY2020Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	20000000	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	25500000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-27000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	227000	USD
CY2021Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	42683000	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	36334000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	41546000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	44683000	USD
CY2021Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	783000	USD
CY2020Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	233000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	2295000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	1131000	USD
CY2021Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1400000	USD
CY2020Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	2471000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-4049000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	9922000	USD
CY2021Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	43300000	USD
CY2020Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	33630000	USD
CY2021Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	43300000	USD
CY2020Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	33630000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	66390000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14922000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	51468000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	21208000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	21208000	USD
CY2021Q3	eols	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	87598000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14922000	USD
CY2021Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	72676000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	65757000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10460000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	55297000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2020Q4	eols	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	86965000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10460000	USD
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	76505000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	844000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3094000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2955000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2955000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2955000	USD
CY2021Q3	eols	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	38665000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	51468000	USD
CY2021Q3	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	0	USD
CY2020Q3	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	432000	USD
	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	633000	USD
	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	1966000	USD
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	843000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1664000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4463000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4813000	USD
CY2021Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	9088000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5485000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	0	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4076000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5751000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3081000	USD
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1655000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	895000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1457000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1050000	USD
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	23436000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9102000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
	eols	Lessee Operating Lease Termination Period LesseeOperatingLeaseTerminationPeriod	P36M
	eols	Lessee Operating Lease Period Of Written Notice Prior To Lease Terminate Date LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate	P12M
	eols	Lessee Operating Lease Termination Fee Period Of Rent Equivalent LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent	P6M
CY2021Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P60M
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	268000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	266000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	797000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	813000	USD
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	20000	USD
CY2020Q3	us-gaap	Variable Lease Cost VariableLeaseCost	5000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	40000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	32000	USD
CY2021Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
CY2020Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	168000	USD
CY2021Q3	us-gaap	Lease Cost LeaseCost	288000	USD
CY2020Q3	us-gaap	Lease Cost LeaseCost	271000	USD
	us-gaap	Lease Cost LeaseCost	837000	USD
	us-gaap	Lease Cost LeaseCost	1013000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.094
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	305000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1265000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1320000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1377000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	115000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4382000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	642000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3740000	USD
CY2021Q3	us-gaap	Purchase Obligation PurchaseObligation	1601000	USD
CY2020Q4	us-gaap	Loss Contingency Number Of Plaintiffs LossContingencyNumberOfPlaintiffs	2	plaintiff
CY2020Q4	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	2	complaint
CY2020Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2021Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55553792	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55553792	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4361291	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.04
CY2021Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1364826	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2476000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2952000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6927000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7954000	USD

Files In Submission

Name	View Source	Status
0001570562-21-000173-index-headers.html	Edgar Link	pending
0001570562-21-000173-index.html	Edgar Link	pending
0001570562-21-000173.txt	Edgar Link	pending
0001570562-21-000173-xbrl.zip	Edgar Link	pending
eols-20210930.htm	Edgar Link	pending
eols-20210930.xsd	Edgar Link	pending
eols-20210930_cal.xml	Edgar Link	unprocessable
eols-20210930_def.xml	Edgar Link	unprocessable
eols-20210930_htm.xml	Edgar Link	completed
eols-20210930_lab.xml	Edgar Link	unprocessable
eols-20210930_pre.xml	Edgar Link	unprocessable
exhibit311q32021.htm	Edgar Link	pending
exhibit312q32021.htm	Edgar Link	pending
exhibit321q32021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EOLS
Evolus, Inc. Stock $eols

2021 Q4 Form 10-Q Financial Statement

#000157056221000173 Filed on November 02, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS Evolus, Inc. Stock $eols

2021 Q4 Form 10-Q Financial Statement

#000157056221000173 Filed on November 02, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS
Evolus, Inc. Stock $eols